<DOC>
	<DOCNO>NCT00283413</DOCNO>
	<brief_summary>The objective Symbiot III Clinical Trial evaluate safety effectiveness Symbiot Covered Stent System treatment symptomatic ischemic saphenous vein bypass graft disease .</brief_summary>
	<brief_title>Symbiot III : A Prospective Randomized Trial Evaluating Symbiot Covered Stent System Saphenous Vein Grafts</brief_title>
	<detailed_description>Symbiot III prospective , multi-center , randomize , control trial evaluate safety efficacy Symbiot stent compare bare metal stent treatment symptomatic ischemic saphenous vein graft disease . Randomization stratify intend use intravenous glycoprotein IIb/IIIa inhibitor intend use approve distal protection ensure approximate balance study treatment within stratum . The primary outcome variable study target lesion percent diameter stenosis 8 month post-implant .</detailed_description>
	<criteria>General 1 . Patient &gt; =18 year old 2 . Patients eligible percutaneous coronary intervention stenting 3 . Patient acceptable candidate repeat CABG 4 . CPK must within ULN day procedure 5 . Patient must meet one follow requirement : treatment one two de novo restenotic lesion single SVG treatment native coronary artery target graft single procedure , provide native artery treat prior randomization target lesion ( ) result MACE TIMI flow &lt; 3 6 . Patients ( legal representative ) understand nature procedure study requirement provide write informed consent study specific test procedure perform 7 . Patient willing comply specify followup evaluation specify time location 8 . Patient angina pectoris ( CCS 1 , 2 , 3 , 4 ) coronary ischemia document positive functional ischemia study 9 . Patient child bear potential negative pregnancy test within 7 day prior treatment Angiographic 1 . Target lesion ( ) locate within single SVG 2 . Reference vessel &gt; =3.5 mm &lt; =5.5mm diameter stent deployment site 3 . Cumulative target lesion length &lt; =41mm 4 . Target lesion ( ) randomize treatment study device must completely cover 1 2 stent ( maximum allowable aggregate stent length target vessel 51 mm ) 5 . Target lesion stenosis &gt; =50 % &lt; 100 % General 1 . Patient currently enrol another IRBapproved trial reach primary endpoint visit still active treatment phase 2 . Patient previously enrol Symbiot Trial 3 . Patient document leave ventricular ejection fraction &lt; 30 % within 30 day enrollment 4 . Patient myocardial infarction within 48 hour prior trial procedure and/or CKMB &gt; 2X ULN 5 . Patient , , plan additional interventional procedure coronary vessel ( coronary artery saphenous vein graft ) meet follow criterion : If stag procedure choose nonstudy percutaneous intervention nontarget vessel : 30 day prior index procedure allow Between 24 hour 30 day prior index procedure allow provide major adverse cardiac event result stag nonstudy procedure Within 24 hour prior index procedure allow Within 30 day index procedure allow 30 day index procedure allow 6 . The lesion treat within 10 mm anastomosis 7 . Patient life expectancy le 1 year due medical condition 8 . The lesion ( ) treat require debulking prior stent placement 9 . Patient preexist condition aspirin contraindicate 10 . Patient preexist condition clopidogrel ticlopidine contraindicate 11 . Patient known hypersensitivity nickel Angiographic 1 . Target vessel left main arteryequivalent graft 2 . Target vessel internal mammary artery graft 3 . Target lesion ( ) intraluminal thrombus present TIMI flow &lt; 3 4 . Target vessel excessive tortuousity unsuitable delivery deployment Symbiot 5 . Target lesion ( ) is/are within previous stented segment 6 . Target nontarget vessel require pretreatment adjunctive nonballoon device ( e.g. , DCA , TEC , Rotablator laser ) prior stent placement stent placement procedure 7 . Treatment nonapproved distal protection system 8 . Target lesion ( ) involve either ostium distal anastomosis 9 . Target lesion ( ) immediately distal &gt; 45 degree bend vessel 10 . Target vessel degenerate SVG ( diffuse segment disease &gt; 41 mm length stenosis , ectasia probable thrombus ) 11 . Untreated lesion present proximal distal target site may compromise inflow outflow treatment site stent deployment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Covered Stent System</keyword>
	<keyword>Saphenous Vein Graft</keyword>
	<keyword>Coronary Artery Bypass [ MeSH ]</keyword>
	<keyword>Stents [ MeSH ]</keyword>
</DOC>